Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2018 Jun 28;16(1):176.
doi: 10.1186/s12967-018-1558-8.

Efficacy and safety of the artificial pancreas in the paediatric population with type 1 diabetes

Susanna Esposito  1 , Elisa Santi  2 , Giulia Mancini  2 , Francesco Rogari  2 , Giorgia Tascini  2 , Giada Toni  2 , Alberto Argentiero  2 , Maria Giulia Berioli  2
Affiliations
Review

Efficacy and safety of the artificial pancreas in the paediatric population with type 1 diabetes

Susanna Esposito et al. J Transl Med. .

Abstract

Background: Type 1 diabetes (DM1) is one of the most common chronic diseases in childhood and requires life-long insulin therapy and continuous health care support. An artificial pancreas (AP) or closed-loop system (CLS) have been developed with the aim of improving metabolic control without increasing the risk of hypoglycaemia in patients with DM1. As the impact of APs have been studied mainly in adults, the aim of this review is to evaluate the efficacy and safety of the AP in the paediatric population with DM1.

Main body: The real advantage of a CLS compared to last-generation sensor-augmented pumps is the gradual modulation of basal insulin infusion in response to glycaemic variations (towards both hyperglycaemia and hypoglycaemia), which has the aim of improving the proportion of time spent in the target glucose range and reducing the mean glucose level without increasing the risk of hypoglycaemia. Some recent studies demonstrated that also in children and adolescents an AP is able to reduce the frequency of hypoglycaemic events, an important limiting factor in reaching good metabolic control, particularly overnight. However, the advantages of the AP in reducing hyperglycaemia, increasing the time spent in the target glycaemic range and thus reducing glycated haemoglobin are less clear and require more clinical trials in the paediatric population, in particular in younger children.

Conclusions: Although the first results from bi-hormonal CLS are promising, long-term, head-to-head studies will have to prove their superiority over insulin-only approaches. More technological progress, the availability of more fast-acting insulin, further developments of algorithms that could improve glycaemic control after meals and physical activity are the most important challenges in reaching an optimal metabolic control with the use of the AP in children and adolescents.

Keywords: Artificial pancreas; Closed-loop system; Glycated haemoglobin; Sensor-augmented pumps; Type 1 diabetes.

PubMed Disclaimer

Figures

Fig. 1
Fig. 1
Composition of artificial pancreas (AP)
See this image and copyright information in PMC

References

    1. Diabetes Control and Complications Trial Research Group. Nathan DM, Genuth S, Lachin J, Cleary P, Crofford O, Davis M, Rand L, Siebert C. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med. 1993;329:977–986. doi: 10.1056/NEJM199309303291401. - DOI - PubMed
    1. Nathan DM, Cleary PA, Backlund JY, Genuth SM, Lachin JM, Orchard TJ, Raskin P, Zinman B, Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications (DCCT/EDIC) Study Research Group Intensive diabetes treatment and cardiovascular disease in patients with type 1 diabetes. N Engl J Med. 2005;353:2643–2653. doi: 10.1056/NEJMoa052187. - DOI - PMC - PubMed
    1. Hsu CR, Chen YT, Sheu WH. Glycemic variability and diabetes retinopathy: a missing link. J Diabetes Complications. 2015;29:302–306. doi: 10.1016/j.jdiacomp.2014.11.013. - DOI - PubMed
    1. de Beaufort C, Rewers MJ, Pillay K, Craig ME, Hanas R, Acerini CL, Maahs DM, International Society for Pediatric and Adolescent Diabetes: ISPAD Clinical Practice Consensus Guidelines 2014 Assessment and monitoring of glycemic control in children and adolescents with diabetes. Pediatr Diabetes. 2014;2014(15):102–114. - PubMed
    1. Bergenstal RM, Tamborlane WV, Ahmann A, Buse JB, Dailey G, Davis SN, Joyce C, Perkins BA, Welsh JB, Willi SM, Wood MA, STAR 3 Study Group Effectiveness of sensor-augmented insulin-pump therapy in type 1 diabetes. N Engl J Med. 2010;363:311–320. doi: 10.1056/NEJMoa1002853. - DOI - PubMed